Shafique Virani
Director/Board Member presso TAUC3 Biologics Ltd.
Patrimonio netto: 1 M $ in data 31/03/2024
Profilo
Shafique Virani is currently a Director at TauC3 Biologics Ltd.
He previously served as the Chief Executive Officer at Navire Pharma, Inc., CoA Therapeutics, Inc., and Biobridge LLC.
Prior to that, he was the Vice President & Global Head-Neuroscience at Genentech, Inc. He holds a doctorate degree from The University of Nottingham.
He is currently serving as the Chief Medical & Business Officer at Recursion Pharmaceuticals, Inc.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
16/01/2024 | 136 748 ( 0.07% ) | 1 M $ | 31/03/2024 |
Posizioni attive di Shafique Virani
Società | Posizione | Inizio |
---|---|---|
TAUC3 Biologics Ltd.
TAUC3 Biologics Ltd. BiotechnologyHealth Technology TAUC3 Biologics Ltd. is engaged in the biotechnology industry. The company was founded on July19, 2019 and is headquartered in London, the United Kingdom. | Director/Board Member | - |
Precedenti posizioni note di Shafique Virani
Società | Posizione | Fine |
---|---|---|
RECURSION PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/06/2023 |
Navire Pharma, Inc.
Navire Pharma, Inc. Pharmaceuticals: MajorHealth Technology Navire Pharma, Inc. engages in the development of therapeutics to treat multiple cancers. It focuses on SHP2, a protein-tyrosine phosphatase that links growth factor, cytokine and integrin signalling with the downstream RAS/ERK MAPK pathway to regulate cellular proliferation and survival. The company was founded by Phil Jones and Benjamin Neel in 2017 and is headquartered in San Francisco, CA. | Chief Executive Officer | 01/12/2019 |
CoA Therapeutics, Inc.
CoA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., CoA Therapeutics, Inc. is a biotechnology company based in San Francisco, CA. The private company is targeting coenzyme-A (CoA) for patients with PKAN, organic acidurias, and other diseases of CoA sequestration. CoA plays a crucial role in energy metabolism and is implicated in a large number of disorders, from ultra-rare diseases like pantothenate kinase-associated neurodegeneration (PKAN) and organic acidurias (OAs), to common diseases such as type 2 diabetes. CoA Therapeutics is developing a novel small-molecule approach to modulate CoA levels by leveraging recent research about the CoA synthetic pathway. The company's approach and lead compounds are based on breakthrough scientific developments led by Suzanne Jackowski, Charles Rock, Richard Lee, and Stephen White at St. Jude Children's Research Hospital. | Chief Executive Officer | 01/12/2019 |
Biobridge LLC | Corporate Officer/Principal | 01/12/2019 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/06/2017 |
Formazione di Shafique Virani
The University of Nottingham | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
RECURSION PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 5 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Navire Pharma, Inc.
Navire Pharma, Inc. Pharmaceuticals: MajorHealth Technology Navire Pharma, Inc. engages in the development of therapeutics to treat multiple cancers. It focuses on SHP2, a protein-tyrosine phosphatase that links growth factor, cytokine and integrin signalling with the downstream RAS/ERK MAPK pathway to regulate cellular proliferation and survival. The company was founded by Phil Jones and Benjamin Neel in 2017 and is headquartered in San Francisco, CA. | Health Technology |
CoA Therapeutics, Inc.
CoA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., CoA Therapeutics, Inc. is a biotechnology company based in San Francisco, CA. The private company is targeting coenzyme-A (CoA) for patients with PKAN, organic acidurias, and other diseases of CoA sequestration. CoA plays a crucial role in energy metabolism and is implicated in a large number of disorders, from ultra-rare diseases like pantothenate kinase-associated neurodegeneration (PKAN) and organic acidurias (OAs), to common diseases such as type 2 diabetes. CoA Therapeutics is developing a novel small-molecule approach to modulate CoA levels by leveraging recent research about the CoA synthetic pathway. The company's approach and lead compounds are based on breakthrough scientific developments led by Suzanne Jackowski, Charles Rock, Richard Lee, and Stephen White at St. Jude Children's Research Hospital. | Health Technology |
TAUC3 Biologics Ltd.
TAUC3 Biologics Ltd. BiotechnologyHealth Technology TAUC3 Biologics Ltd. is engaged in the biotechnology industry. The company was founded on July19, 2019 and is headquartered in London, the United Kingdom. | Health Technology |
Biobridge LLC |
- Borsa valori
- Insiders
- Shafique Virani